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Abstract 
Angiotensin II, a vasoconstrictor and the main effector molecule of the renin-angiotensin 
system, is known to influence inflammation, thrombosis, LDL oxidation and growth 
factors, all of which contribute to cardiovascular disease. The associations of 
polymorphisms in the angiotensin-converting enzyme 2 (ACE2) gene with cardiovascular 
risk have not been fully determined.  Tag single nucleotide polymorphisms (SNPs) in 
ACE2 were genotyped in participants of the prospective MORGAM study (N=5 092) from 
five cohorts: ATBC, FINRISK, Northern Sweden, PRIME/Belfast and PRIME/France. 
Using a case-cohort design, associations were sought between SNPs and haplotypes with 
cardiovascular events during follow-up (Cox proportional hazards model).  The comparison 
group were a subset of all MORGAM participants who were selected to ensure similar age 
and sex distributions among the cases and controls. The A allele of the rs2285666 SNP 
(HR=0.3, p=0.04) was significantly associated with the risk of cardiovascular death in 
female subjects.  These findings complement those found in other studies of SNPs in the 
ACE2 gene in relation to cardiovascular disease risk. As females carry two copies of the 
ACE2 gene and given its plausible biological role in cardiovascular disease risk, further 
studies of ACE2 should be prioritised.  
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Introduction 
The Renin Angiotensin System (RAS) plays important roles in the regulation of blood 
pressure (BP) and electrolyte balance, and also in the pathogenesis of cardiovascular 
disease (CVD) 1,2. In the first and rate limiting step of the RAS, renin (REN) catalyses the 
cleavage of angiotensinogen into angiotensin I. Angiotensin I can then be further catalysed 
to angiotensin II, the main effector mol cule of the renin-angiotensin system, by 
angiotensin converting enzyme. Angiotensin II mediates its effects through promotion of 
inflammation, production of growth factors3, thrombosis4 and LDL oxidation4  , all of 
which contribute to the risk of myocardial infarction (MI) and stroke. Additionally, 
angiotensin II is a potent vasoconstrictor which raises blood pressure and thus plays an 
important role in the pathogenesis of hypertension5,6. Renin-angiotensin system inhibition 
by the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in 
experimental animal models of atherosclerosis have demonstrated a reduction in vascular 
lesions7, and of myocardial damage in both a coronary occlusion reperfusion model8 and a 
myocardial stunning model9. Clinical trials have shown a reduction in myocardial infarction 
and stroke in subjects taking angiotensin converting enzyme inhibitors in comparison to 
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placebo10 and also that angiotensin receptor blockers may be as effective as angiotensin 
converting enzyme inhibitors at lowering risk of cardiovascular disease 11.  
More recently, however, some important additional pathways in the RAS have been 
elucidated. These include the discovery that there is a second angiotensin converting 
enzyme (ACE2) which catalyses the conversion of angiotensin I and angiotensin II, to 
angiotensin(1-9) and angiotensin(1-7), respectively 12-14. Angiotensin(1-9) is an inactive 
nonapeptide, while angiotensin(1-7) appears to act as a natural antagonist for angiotensin II, 
in that it has potent vasodilator, natriuretic, antigrowth and endothelium protective 
properties 15.  
To date, many candidate gene studies in humans have tested the association of 
polymorphisms in various components of the renin-angiotensin system, particularly the 
angiotensinogen, angiotensin converting enzyme and angiotensin II type 1 receptor genes, 
with the risk of hypertension and cardiovascular disease16.  By contrast, just a limited 
number of association studies have looked at polymorphisms in the ACE2 gene in relation 
to cardiovascular disease risk17,18 and blood pressure variation19,20.  
This study aimed to further examine the associations of genetic variants in ACE2 
with cardiovascular morbidity and mortality by genotyping tag SNPs in participants of the 
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MORGAM project, an international pooling of prospectively collected cardiovascular 
cohorts.  
Materials and Methods 
Study populations 
The MORGAM study is a European-wide prospective study of cardiovascular disease risk, 
consisting of 33 282 participants21.  This work is based on a subset of MORGAM subjects:  
the Finnish ATBC study cohort, the FINRISK cohort from Finland, the Northern Sweden 
cohort, the PRIME cohort from Belfast, Northern Ireland and the PRIME cohort from 
France. Risk factors measured at baseline in each cohort included sex, height, weight, 
smoking status, total and high-density lipoprotein (HDL) cholesterol, systolic and diastolic 
blood pressure (two readings) and previous history of CVD or diabetes. Data on all-cause 
mortality and on all fatal or non-fatal stroke events (ischemic or hemorrhagic) and coronary 
heart disease events (definite and possible acute MI or coronary death or unstable angina 
pectoris), was collected during the follow-up period. Ischemic and haemorrhagic strokes 
could not be distinguished in all cohorts and so stroke types are pooled in the analysis. The 
MORGAM cohorts has been described in detail elsewhere22.  The study was approved by 
local ethics committees and each subject gave written informed consent. 
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 A case-cohort design has been adopted in the MORGAM study whereby a random 
subset of participants underwent genotyping as well as all additional individuals who 
experienced CVD events during the follow-up.23 This random subset of participants, the 
subcohort, was selected according to population-specific sampling probabilities which were 
dependent on age and sex distributions in order to ensure that these were similar in the 
subcohort and the cases.   
Identification of Gene Sequence Variants and Genotyping 
Genomic DNA was extracted from leukocytes by a salting out procedure24.  DNA from 20 
Irish subjects (10 normotensive and 10 hypertensive) was screened for mutations in the 
known promoter (-1 224 to +121) and protein coding regions (18 exons, >40bp of flanking 
intronic regions) of the ACE2 gene. As previously described, this was achieved by a 
combination of ion-pairing reversed-phase partially denaturing high-performance liquid 
chromatography and direct sequencing25.  Just three ACE2 SNPs were detected, and so all 
of the seven SNPs in ACE2 that were found in dbSNP (http://www.ncbi.nlm.nih.gov/SNP, 
build 121, Jun 2004) with a minor allele frequency of >1% in any ethnic group were 
selected for genotyping. However, four of the SNPs from dbSNP were found to be 
monomorphic in the Irish subjects (rs4646179, rs4646116, rs4646114, rs4646113) and 
assays could not be optimised for the other three (rs4646115, rs4646112, rs2097723). 
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While rs2097723 has been found at a minor allele frequency of 30% in the HapMap 
Caucasian population, all other SNPs are monomorphic in Caucasian populations and 
polymorphic only in African populations according to dbSNP.  Thus, of the three SNPs 
identified by sequencing, two were in very tight linkage disequilibrium (r2=0.99) leaving 
just two SNPs for further study, eliminating the need to formally identify tagging SNPs. 
Hence these two SNPs were genotyped in the MORGAM subjects. Genotyping of SNPs 
was performed by KBiosciences (Herts, U.K.) using modified TaqMan assays 
(www.kbiosciences.co.uk). 
Statistical analysis 
Statistical analyses were performed using the Stata statistical package (version 8.2, 
StataCorp, College Station, Texas). Phenotypic data were expressed as mean ± SD or as 
numbers (percentages). Two way ANOVAs and Chi-squared tests were used to compare 
phenotypic variables across the five cohorts. 
Departure from Hardy–Weinberg equilibrium was assessed using Chi-squared tests 
with 1-degree of freedom. An additive genetic model was used for all SNP analyses - this 
assumption was tested through comparison of the fit of an additive model with the fit of a 
two-degree of freedom pairwise comparison in a likelihood ratio test. Haplotypes of the 
SNPs in the ACE2 genes were inferred using the “--hap-phase” function in Plink (version 
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1.04, http://pngu.mgh.harvard.edu/purcell/plink/)26 with a haplotype frequency cut-off of 
5% in any cohort. Each haplotype was compared to a reference haplotype representing the 
most frequently occurring haplotype and the analyses were weighted according to 
haplotype probability. All haplotype analyses were performed in Stata. 
A Cox proportional hazards model was used to test for the associations of each of 
the SNPs and haplotypes with all prospective stroke or MI events, all fatal prospective 
stroke or MI events, all prospective MI events and all prospective stroke events using the 
time-to-event in days. Each of these models was stratified by history of stroke or MI at 
baseline, and adjusted for age, smoking, MORGAM cohort, body mass index (BMI), 
history of cardiovascular events (stroke or MI) at baseline, history of diabetes and ratio of 
total cholesterol to HDL. Due to the case-cohort design, a robust variance estimator was 
applied to account for the fact that some of the members of the subcohort were also cases23. 
The subject identifiers were used as the cluster variable. Cases outside the subcohort were 
given a weight of one, non-cases in the subcohort were weighted with the inverse of the 
subcohort sampling probability, while cases in the subcohort require two records - one 
censored observation for the time before the event with inverse sampling probability weight 
and one uncensored observation from the time before the event with weight one. These 
weights were included as an offset in the analysis.   
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Linear regression analysis was used to look for associations between the SNPs and 
haplotypes with systolic and diastolic baseline blood pressure (average of the two readings) 
in all members of the subcohort, adjusted for the same covariates. Subjects who had been 
taking blood pressure lowering medication within the 2 weeks prior to baseline had a 
correction factor applied (an additional 15mmHg systolic and 10mmHg diastolic)27.  
The Cox proportional hazards and the linear regression analyses were also 
performed in each of the five cohorts separately. As the ACE2 gene is on the X 
chromosome, separate analyses were performed for males and females. Associations with 
p<0.05 were considered to be statistically significant. 
Results 
Population description 
The baseline characteristics of each of the cohorts are described in Table 1. Only the 
FINRISK and the Northern Sweden cohorts included women. For the Cox proportional 
hazards analysis, there were 1 959 cardiovascular disease cases and 2 278 subcohort 
members, with 387 subjects who were both cases and members of the subcohort. The linear 
regression analysis was performed on all 2 278 subcohort members. 
Genetic data 
Page 10 of 31
Journal of the Renin-Angiotensin-Aldosterone System
JRAAS
For Peer Review
 11 
The overall genotyping success rate was 96% and the rate of discrepancies between blinded 
duplicate samples was 0.07%. Both SNPs were found to be in Hardy Weinberg equilibrium 
in all cohorts. In general, the three Scandinavian cohorts had similar minor allele and 
haplotype frequencies, often differing from that of the two PRIME cohorts (Tables S1).  
Associations of individual SNPs and haplotypes with CVD events 
There were no significant associations between any of the SNPs or haplotypes with all 
prospective MI and stroke events, prospective MI events only or prospective stroke events 
only (Table 2 and Table S2). The A allele of rs2285666 was found to be associated with a 
decreased risk of fatal stroke and MI events in female subjects (HR=0.3, p=0.04) (Figure 
1).  
Associations of individual SNPs and haplotypes with BP 
There were no significant associations between the SNPs and haplotypes of ACE2 and 
blood pressure (Figure 2). 
Discussion 
This study demonstrates that the A allele of the rs2285666 polymorphism in the ACE2 gene 
influences the risk of fatal CVD events in female participants of the MORGAM study. As 
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the ACE2 gene is located on the X chromosome, this study has investigated the risk of the 
SNPs independently in males and females, who have one and two gene copies, respectively.  
In a study of a Chinese Han population, the rs2285666 SNP was found to increase 
the risk of MI in females, though the result was not significant (p=0.06)18. The same study 
showed that two other SNPs in the ACE2 gene (rs1978124 and rs4646142) were 
significantly associated with risk of MI in females18. A study of left ventricular mass and 
septal wall thickness in German males did not find any association with rs2285666, but 
found significant associations between other SNPs in the ACE2 gene (rs4646156, rs879922, 
rs4240157 and rs233575) and these measures28. Two further SNPs in the ACE2 gene 
(rs2106809 and rs6632667) were found to be associated with risk of hypertrophic 
cardiomyopathy in Chinese males29. Another study in a Chinese population revealed that 
male carriers of the A allele of rs2285666 had lower interventricular septal end-diastolic 
thickness and lower left ventricular mass than G allele carriers in patients with type II 
diabetes30.  
Given these gender and ethnic-group differences, it is likely that there is differing 
linkage disequilibrium between Europeans and Asians in the ACE2 gene. Interestingly, A is 
the minor allele of this SNP in our study (frequency=19%) and in the study of German 
subjects (frequency=23%)28, whereas the frequency of both alleles is around 50% in the 
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Chinese populations18,29,31. All of this data combined indicates a sex- and race-dependent 
role of variants in the ACE2 gene on cardiovascular disease risk. Gender differences in the 
RAS with respect to CVD and blood pressure have been noted previously and have been 
attributed to hormonal effects 32. However, the fact that females carry two copies of the 
ACE2 gene while men only carry one cannot be ruled out as a factor contributing to such 
differences. The likely role for ACE2 in CVD is via its effects on levels of both angiotensin 
II and angiotensin (1-7).  
One of the strengths of the prospective case-cohort study design in the MORGAM 
project above that of retrospective studies is that it allows for the study of fatal events that 
occur during the follow-up period. Genetic variants that predispose to the more acute events 
that cause mortality cannot be determined from retrospective studies.  
The tag SNPs selected for this study were chosen based on sequencing and 
genotyping in an Irish population. This approach was used before the release of HapMap 
data, which indicates that five tag SNPs in ACE2 would be necessary to represent 85% of 
the genetic variation in that gene (www.hapmap.org, release #27). Rs2285666 has not been 
genotyped as part of the HapMap project, however. LD data from other studies has 
indicated that there is strong LD within the ACE2 gene 18,28.  It is difficult to say how well 
the SNPs we have selected accounted for the genetic variation in the MORGAM cohorts.  
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Conclusions 
The analyses of these tag SNPs in this study have indicated some interesting 
findings, and have replicated the findings of other studies. Therefore further investigation 
of the ACE2 gene in relation to CVD risk in other populations should be prioritised. 
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Titles and legends to figures 
Figure 1 Results of association between fatal cardiovascular disease events during follow-
up (hazard ratio, 95% confidence intervals) with each SNP and haplotype in the ACE2 
gene. * indicates results significant at p<0.05. ‡ compared to wild type haplotype GG. 
Page 19 of 31
Journal of the Renin-Angiotensin-Aldosterone System
JRAAS
For Peer Review
 20 
 
Page 20 of 31
Journal of the Renin-Angiotensin-Aldosterone System
JRAAS
For Peer Review
 21 
Table 1: Baseline characteristics of the MORGAM case-cohort subjects 
 ATBC FINRISK Northern Sweden PRIME/Belfast PRIME/France 
Total, n 1 983 2 146 332 332 299 
Men (%) 1 983 (100) 1 487 (69) 219 (66) 332 (100) 299 (100) 
Mean age at baseline, years 63.6±5.0* 57.3±9.9 57.7±10.2 55.0±2.9 55.3±3.0 
Current daily smoker (%) 1,544 (78)* 537 (25) 67 (20) 98 (30) 78 (26) 
Mean BMI, kg/m2 26.8±4.3 28.1±4.4* 27.1±4.0 26.4±3.3 26.9±3.7 
Drug treatment for high cholesterol (%) 0 (0) 175 (8) 11 (3) 5 (2) 44 (15)* 
Drug treatment for high blood pressure (%) 0 (0)* 548 (26) 77 (23) 34 (10)* 69 (23) 
History of MI (%) 261 (13) 426 (20) 65 (20) 37 (11) 9 (3) 
History of stroke (%) 138 (7) 247 (12) 43 (13) 2 (1) 3 (1) 
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Diabetes (%) 142 (7) 224 (10) 27 (8) 15 (5)* 28 (9) 
Mean systolic blood pressure at baseline, mmHg 142.6±19.0 145.6± 21.6* 139.1±21.9 137.7± 23.6 136.8±18.6 
Mean diastolic blood pressure at baseline, mmHg 84.9±10.4 85.4±11.6 83.4±12.3 82.9±12.1* 85.3±11.7 
Mean HDL cholesterol, mmol/L (SD) 1.2±0.3 1.3±0.4 1.3±0.4 1.1± 0.3* 1.2±0.3 
Mean total cholesterol, mmol/L (SD) 5.9±1.1 5.8±1.1 6.6±1.2* 6.0±1.1 5.7±1.0 
Data expressed as mean ± SD or as number (%), * indicates characteristics of a particular cohort that is statistically significantly different 
(p<0.05) from the other groups 
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Table 2: Results of survival analysis showing the hazard ratio’s and 95% confidence intervals of the association between each SNP and 
haplotype with all cardiovascular events, fatal cardiovascular  events, MI events and stroke events that occurred during the follow-up 
period.  
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  All Cardiovascular events Fatal cardiovascular events MI Stroke 
Males N=1382 N=453 N=1014 N=448 
 HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI] 
SNPs rs2285666 (A allele)  0.97 [0.83-1.12] 0.87 [0.67-1.13] 0.93 [0.78-1.11] 1.12 [0.88-1.44] 
 rs971249 (A allele) 1.10 [0.97-1.25] 1.17 [0.95-1.44] 1.17 [1.01-1.36] 0.92 [0.73-1.14] 
Haplotypes GA  1.09 [ 0.95-1.26] 1.16 [0.92-1.46] 1.16 [0.98-1.37] 0.93 [0.73-1.1] 
 AG  1.04 [0.88-1.22] 0.98 [0.74-1.31] 1.04 [0.86-1.26] 0.93 [0.73-1.18] 
Females N=183 N=33 N=93 N=96 
SNPs rs2285666 (A allele) 0.86 [0.60-1.25] 0.27 [0.08-0.97]* 0.87 [0.53-1.42] 0.98 [0.62-1.55] 
 rs971249 (A allele) 1.20 [0.92-1.55] 1.49 [0.92-2.41] 1.18 [0.85-1.63] 1.19 [0.85-1.67] 
Haplotypes GA  1.27 [0.94-1.70] 1.58 [0.87-2.86] 1.31 [0.90-1.91] 1.27[0.86-1.87] 
 AG  0.96 [0.66-1.41] 0.46 [0.16-1.29] 0.97 [0.61-1.56] 1.09 [0.64-1.84] 
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HR=Hazard ratio, 95% CI = 95% confidence intervals, *indicates statistically significant association at p<0.05, ‡ compared to wild type 
haplotype GG
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Supplementary data 
Annex 1: Sites and key personnel of contributing MORGAM Centres 
Finland 
FINRISK, National Institute for Health and Welfare, Helsinki: V. Salomaa (principal 
investigator), A. Juolevi, E. Vartiainen, P. Jousilahti; 
ATBC, National Institute for Health and Welfare, Helsinki: J. Virtamo (principal 
investigator), H. Kilpeläinen; 
MORGAM Data Centre, National Institute for Health and Welfare, Helsinki: K. 
Kuulasmaa (head), Z. Cepaitis, A. Haukijärvi, B. Joseph, J. Karvanen, S. Kulathinal, M. 
Niemelä, O. Saarela; 
MORGAM Central Laboratory, National Institute for Health and Welfare, Helsinki: M. 
Perola,   (responsíble person), K. Silander, M. Alanne, P. Laiho, K. Kristiansson, K. 
Ahonen; 
France 
National Coordinating Centre, National Institute of Health and Medical Research 
(U258), Paris: P. Ducimetière (national coordinator), A. Bingham; 
PRIME/Strasbourg, Department of Epidemiology and Public Health, EA 3430, 
Strasbourg University, Faculty of Medicine, Strasbourg: D. Arveiler (principal 
investigator), B. Haas, A. Wagner; 
PRIME/Toulouse, Department of Epidemiology, Toulouse University School of 
Medicine, Toulouse: J. Ferrières (principal investigator), J-B. Ruidavets, V. Bongard, D. 
Deckers, C. Saulet, S. Barrere; 
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PRIME/Lille, Department of Epidemiology and Public Health, Pasteur Institute of Lille: 
P. Amouyel (principal investigator), M. Montaye, B. Lemaire, S. Beauchant, D. Cottel, 
C. Graux, N. Marecaux, C. Steclebout, S. Szeremeta; 
MORGAM Laboratory, INSERM U525, Paris: F. Cambien (responsible person), L. 
Tiret, V. Nicaud; 
Sweden 
Northern Sweden, Umeå University Hospital, Department of Medicine, Umeå: P-G 
Wiklund   (principal investigator), K. Asplund (former principal investigator), B. 
Stegmayr (former principal investigator) S. Nasic, G. Rönnberg, Å. Johansson, V. 
Lundberg, E. Jägare-Westerberg, T. Messner; 
United Kingdom 
PRIME/Belfast, Queen's University Belfast, Belfast, Northern Ireland: F. Kee (principal 
investigator) A. Evans (former principal investigator), J. Yarnell, E. Gardner; 
MORGAM Coordinating Centre, Queen's University Belfast, Belfast, Northern Ireland: 
A. Evans (MORGAM coordinator), S. Cashman, F Kee; 
MORGAM Management Group: A. Evans (chair), S. Blankenberg (Mainz, 
Germany), F. Cambien, M. Ferrario (Varese, Italy), K. Kuulasmaa, A. Palotie (Hinxton, 
England), M. Perola, A Peters (Munich, Germany), V. Salomaa, P-G Wiklund, H. 
Tunstall-Pedoe (Dundee, Scotland); Former members: K. Asplund (Stockholm, 
Sweden), L. Peltonen (Helsinki, Finland), D. Shields (Dublin, Ireland), B. Stegmayr. 
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Table S1: Minor allele and haplotype frequencies by cohort 
SNPs rs number Minor allele ATBC 
FINRISK 
 (M) 
 FINRISK  
(F) 
Northern 
Sweden (M) 
Northern 
Sweden (F) 
PRIME/ 
Belfast  
PRIME/ 
France  
Int3 9570 rs2285666 A 0.19 0.21 0.20 0.23 0.17 0.15 0.18 
Int4 12268 rs971249 A 0.30 0.32 0.29 0.29 0.32 0.39 0.39 
 
SNPs 
       
rs2285666 rs971249        
G G 0.49 0.37 0.44 0.49 0.50 0.45 0.42 
G A 0.29 0.27 0.27 0.29 0.32 0.37 0.37 
Haplotypes 
A G 0.18 0.17 0.18 0.22 0.17 0.14 0.18 
Int=intron, M=male subjects, F= female subjects, rs number=dbSNP reference number 
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Table S2: Results of Cox proportional hazard analysis of the association between SNPs and haplotypes with CVD death in each cohort 
  ATBC FINRISK Northern Sweden PRIME/Belfast PRIME/France 
Males N=277 N=139 N=9 N=22 N=7 
  HR[95% CI] HR[95% CI] HR[95% CI] HR[95% CI] HR[95% CI] 
SNPs rs2285666 (A allele) 0.85 [0.61-1.19] 0.91 [0.56-1.46] -† 0.26 [0.05-1.36] 2.10 [0.45-9.84] 
 rs971249 (A allele) 1.28 [0.98-1.68] 1.03 [0.70-1.52] 9.38 [0.94-92.84] 0.68 [0.21-2.13] 0.23 [0.02-2.06] 
Haplotypes‡ GA 1.29 [0.97-1.72] 0.97 [0.61-1.54] 2.80 [0.54-14.93] 0.42 [0.14-1.25] 0.23 [0.02-2.31] 
 AG 0.96 [0.67-1.38] 0.99 [0.57-1.70] -† 0.19 [0.04-1.07] 1.29 [0.24-6.89] 
Females N=0 N=32 N=1 N=0 N=0 
SNPs rs2285666 (A allele) - 0.30 [0.08-1.06] -† - - 
 rs971249 (A allele) - 1.51 [0.93-2.44] -† - - 
Haplotypes‡ GA - 1.63 [0.89-2.97] -† - - 
 AG - 0.51 [0.18-1.47] -† - - 
HR=Hazard ratio, 95% CI = 95% confidence intervals, † = not enough data to perform analysis due to small sample size, ‡ compared to 
wild type haplotype GG 
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